Camurus AB
CAMX.STDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
CAM2029 Phase 3 Est. Readout
Estimated primary completion for CAM2029 trial (NCT05050942) in Gastro-enteropancreatic Neuroendocrine Tumor. Topline data typically follows completion by weeks to months.
SourceCAM2029
Gastro-enteropancreatic Neuroendocrine Tumor
CAM2029 (octreotide subcutaneous depot)
Acromegaly
octreotide FluidCrystal® injection depot
Acromegaly
leuprolide acetate FluidCrystal® injection depot
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAM2029 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor | - | - |
CAM2029 (octreotide subcutaneous depot) | Phase 3 | Acromegaly | - | - |
octreotide FluidCrystal® injection depot | Phase 2 | Acromegaly | - | - |
leuprolide acetate FluidCrystal® injection depot | Phase 2 | Prostate Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Camurus AB's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Camurus AB's (CAMX.ST) pipeline across Phase 3, Phase 2. Its lead program is CAM2029 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Camurus AB's next FDA catalyst?→
Camurus AB's (CAMX.ST) next tracked catalyst is a Phase 3 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CAMX.ST biotech catalysts?→
Add CAMX.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Camurus AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.